Literature DB >> 16624657

Discrepancies in cancer mortality estimates.

Ernesto Goldman1, James L Fisher.   

Abstract

Progress against cancer-associated mortality could be estimated by mortality rates. However, population-based measures may not be comparable to trends across time based on individual cases followed over time. For two leading cancer types (colorectal and lung and bronchus), the following were calculated from the Surveillance, Epidemiology, and End Results (SEER) Program survival matrix output: probability of death (PD) as the relative cumulative deaths in a cohort of cancer patients at 12-month intervals after the year of diagnosis, 5-year survival probability, and median survival time. Annual age-adjusted U.S. mortality rates were obtained from the National Center for Health Statistics (NCHS). Colorectal cancer PD 5-year (patients having survived up to 5 years after diagnosis) decreased 4.3% from 1985-1997, in contrast to a 20% decrease in the mortality rate during the same period. The mortality rate for lung and bronchus cancer sharply increased between 1973 and 1991 and was followed by a clear downward trend of 2.5% from 1991-1997, while its PD 5-year decreased by only 0.79%. PD for specific cohorts at yearly intervals did not improve across time at comparable intervals; however, the mortality rate was clearly reduced for both anatomic sites. Survival and PD were, as expected, inversely related. Changes in median survival and 5-year survival probability were similar over time. Although the cancer mortality rate is a clear statistical end-point, inference of success by its falling trend alone could be unrelated to the SEER probability of death.

Entities:  

Mesh:

Year:  2006        PMID: 16624657     DOI: 10.1016/j.arcmed.2005.09.013

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  4 in total

1.  Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value.

Authors:  Hui Liu; Lutao Du; Zhihua Wen; Yongmei Yang; Juan Li; Lili Wang; Xin Zhang; Yimin Liu; Zhaogang Dong; Wei Li; Guixi Zheng; Chuanxin Wang
Journal:  Int J Colorectal Dis       Date:  2013-03-10       Impact factor: 2.571

2.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

3.  MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion.

Authors:  Ge Yu; Hui Li; Xin Wang; Tao Wu; Jing Zhu; Shanjun Huang; Yuanlian Wan; Jianqiang Tang
Journal:  Mol Cell Biochem       Date:  2013-05-12       Impact factor: 3.396

4.  Periostin expression and its prognostic value for colorectal cancer.

Authors:  Zewu Li; Xin Zhang; Yongmei Yang; Sanhui Yang; Zhaogang Dong; Lutao Du; Lili Wang; Chuanxin Wang
Journal:  Int J Mol Sci       Date:  2015-05-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.